It is approved for unresectable HER2+ breast cancer in patients who have received two or more anti-HER2 therapies [14], HER2-low or -ultralow breast cancer [15], and HER2+ non-small cell lung cancer (NSCLC) [16] and gastric adenocarcinoma [17]. Here, ERBB2 is linked to gastric adenocarcinoma.